Gamma glutamyl transferase - an underestimated marker for cardiovascular disease and the metabolic syndrome.
Gamma glutamyl transferase - an underestimated marker for cardiovascular disease and the metabolic syndrome.
复制标题
DOI：
10.18433/jpps30923
复制
发表时间：
2020-01-01
期刊：
影响因子：
--
通讯作者：
Chertin, Lucy
中科院分区：
文献类型：
--
作者：
Neuman, Manuela G;Malnick, Stephen;Chertin, Lucy
谷氨酰转移酶（GGT）是一种参与谷胱甘肽和半胱氨酸代谢的酶。GGT是反映胆道受累情况的标准肝酶试验。它还具有抗氧化活性和对内皮功能障碍的调节作用。GGT与代谢综合征有关，并且在NAFLD患者中经常升高。GGT活性在心血管疾病的几个方面也有作用。GGT升高与心血管死亡率、心房颤动、充血性心力衰竭加重有关。此外，它还与阻塞性睡眠呼吸暂停有关。我们回顾了现有的证据，并建议有必要进一步评估GGT的使用，以及是否存在代谢综合征作为预后标志物。
Gamma glutamyl transferase (GGT) is an enzyme in glutathione and cysteine metabolism. GGT is a standard liver enzyme test reflecting biliary tract involvement. It also has a prooxoidant activity and a modulating influence on endothelia dysfunction. GGT is associated with the metabolic syndrome and is often elevated in patients with NAFLD. There is also a role for GGT activity in several aspects cardiovascular disease. There is an association between elevated GGT and cardiovascular mortality, atrial fibrillation, exacerbation of congestive heart failure . In addition there is an association with obstructive sleep apnea. We review the evidence available and suggest that there is a need for further assessing the use of GGT, together with the presence of the metabolic syndrome as a prognostic marker.